Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, discusses ways to optimize treatment for patients with high-risk myelodysplastic syndromes (HR-MDS). Dr Brunner notes that, despite recent advances in supportive care and allogeneic transplantation, no significant change has occurred in the field of chemotherapy for this patient group. Dr Brunner further explains that efforts should be made going forward to improve response rates and quality during different phases of HR-MDS treatment, such as initial treatment, transplantation, and long-term care. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
